Poland – Medical consumables – Dostawa akcesoriów i wyposażenia do aparatury medycznej II

Poland – Artificial joints – Dostawa endoprotez oraz innych implantów (elementów).

Poland – Surgical implants – IMPLANTY NEUROCHIRURGICZNE

Poland – Miscellaneous medical devices and products – Dostawa wyrobów medycznych.

Poland – Imaging equipment for medical, dental and veterinary use – Zakup i dostawa TOMOGRAFU KOMPUTEROWEGO w ramach realizacji przedsięwzięcia pn. „Wyposażenie Zintegrowanego Bloku Operacyjnego w Wojewódzkim Szpitalu Zespolonym w Kielcach”

Poland – Disposable non-chemical medical consumables and haematological consumables – Dostawa jałowych wyrobów medycznych jednorazowego użytku do Szpitala Praskiego p.w. Przemienienia Pańskiego Sp. z o. o. w Warszawie

Poland – Pharmaceutical products – DOSTAWA PŁYNÓW INFUZYJNYCH, ŚRODKÓW SPOŻYWCZYCH SPECJALNEGO PRZEZNACZENIA ŻYWIENIOWEGO

The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots. There are two funding opportunities per year that are open to all targets.